Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Steffen Steurer

Martin Steegmaier

Peter Ettmayer

Bernd Krist

Georg Dahmann

Andreas Schoop

Andreas Mantoulidis

Ulrike Weyer-Czernilofsky

Maria Impagnatiello

Darryl McConnell

Bodo Betzemeier

Irene Waizenegger

Thomas Gerstberger

Christian Klein

Frank Himmelsbach

Matthias Grauert

Matthias Hoffmann

Alexander Pautsch

Walter Spevak

Martin Lenter

Helmut Wittneben

Christoph Hoenke

Stefan Scheuerer

Steffen Breitfelder

Trixi Brandl

Frank Hilberg

Anthony S Prokopowicz

Dirk Kessler

Gisela Schnapp

Ioannis Sapountzis

Udo Maier

Lars Van Der Veen

Ralph Brueckner

Andreas Zoephel

Michael Gmachl

Charlotte Reither

Norbert Schweifer

Oliver Simon

Andreas Schnapp

Iris Kauffmann-Hefner

Matthias Treu

Stephan Karl Zahn

Nina Kerres

Alessio Ciulli

Pilar Garin-Chesa

Laetitia Martin

Anthony S Prokopowicz, Iii

Manfred Koegl

Darryl McConnel

Gisela Schapp

Christian Dank

Emelyne Diers

Michael Roy

Nicole Trainor

William Farnaby

Xiao-Ling Cockcroft

Pilar Garin-chesa

Darryl Mcconnell

The present invention encompasses compounds of formula (1) wherein the groups R, A, G, LK and t have the meanings given in the claims and specification, their use as degraders of SMARCA2 and/or SMARCA4, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

Proteolysis targeting chimera (PROTACS) as degraders of SMARCA2 and /or SMARCA4

The present invention encompasses compounds of general formula (I) wherein the groups Rto R, Xand Xhave the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, e.g. cancer, pharmaceutical preparations containing such compounds and their uses as a medicament. 

Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9

The present invention encompasses compounds of formula (I), wherein the groups Rto R, X, Y and W have the meanings given in the claims and specification, their use as inhibitors of BCL6, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases. 

6-amino-quinolinone compounds and derivatives as BCL6 inhibitors

The present invention encompasses compounds of general formula (1) where in the groups Rto Rand L are defined as in claim, which are suitable for the 5 treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments. 

B-RAF kinase inhibitors

The present invention encompasses compounds of general formula (1), wherein the groups Rto Rand L are defined as in claim, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties. 

Chemical compounds

The present invention encompasses compounds of general formula (1) wherein the groups Rto Rand L are defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments. 

Pyridyltriazoles

The present invention relates to new compounds of general formula (I), wherein the groups Rto R, X, X, Xand Lare defined as in claim, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof in such a treatment. 

Substituted heteroaryl inhibitors of B-RAF

The present invention encompasses compounds of general formula (I) wherein the groups Rto R, A, X and m are defined as in claim, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors

The present invention encompasses compounds of general formula (1) wherein the groups Rto R, X, X, X, Land Lare defined as in claim, which are suitable for the treatment of diseases characterized by excessive or anomalous cell proliferation, and the use thereof in such a treatment. 

Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors

The present invention relates to trisubstituted pyrimidines of formula (I) wherein

Pyrimidine derivatives

The present invention encompasses compounds of the general formula (1) in which

Thiazolyl-dihydro-indazoles

The present invention encompasses compounds of general formula (1) wherein the groups Rto R, L, Q and n are defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

The present invention encompasses compounds of general formula (1) wherein

Thiazolyl-dihydro-indazole

The present invention encompasses compounds of general formula (1) whereinRto Rare defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

The invention relates to pyrrolobenzimidazolone compounds of formula (I), wherein A, T and Rto Rare defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation and the use thereof for preparing a pharmaceutical composition.

Pyrrolobenzimidazolones and their use as anti-proliferative agents

Growing community of inventors

Vienna, Austria

Steffen Steurer